In light of the FLAURA2 data, which patients would you recommend upfront treatment with chemotherapy + osimertinib rather than osimertinib monotherapy?
Answer from: Medical Oncologist at Academic Institution
The management of patients with advanced, classical (i.e., exon 19 deletion/L858R) EGFR mutation-positive NSCLC has been fairly straightforward since the approval of osimertinib for frontline management based on the outstanding results of the FLAURA study demonstrating significantly improved PFS and...
Comments
Medical Oncologist at Florida Cancer Specialists and Research Institute Thank you very much for this thoughtful response!
Medical Oncologist at Kaiser Permanente Great analysis!
Medical Oncologist at Moffitt Cancer Center This was very helpful. Thanks Dr. @Halmos!
Thank you very much for this thoughtful response!
Great analysis!
This was very helpful. Thanks Dr. @Halmos!
Thank you!